The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

The US Food and Drug Administration FDA has approved French pharmaceutical company Sanofi Dupixent an anti-bronchitis drug ...

Human Metapneumovirus (hMPV) can be deadly in extreme cases but unlike other similar illnesses, there is no vaccine for it.

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

Changes in people’s voices recoded on a smartphone can signal a serious flare up in symptoms of chronic obstructive pulmonary ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...

PARIS, France and TARRYTOWN, NY, USA I7, 2024 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.